Discounted Cash Flow (DCF) Analysis Unlevered

Phio Pharmaceuticals Corp. (PHIO)

$0.6151

+0.00 (+0.18%)
All numbers are in Millions, Currency in USD
Stock DCF: -1,718.52 | 0.6151 | overvalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 0.010.140.0200.010.040.140.451.434.57
Revenue (%)
EBITDA -14-7.28-8.84-8.720.08-30.13-96.02-305.99-975.07-3,107.18
EBITDA (%)
EBIT -14.07-7.36-8.91-8.79--30.40-96.88-308.72-983.77-3,134.90
EBIT (%)
Depreciation 0.070.080.070.070.080.270.862.738.7027.72
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash 3.5814.886.9314.2424.0650.26160.15510.331,626.235,182.18
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable 0.510.550.810.730.282.347.4523.7375.63241.01
Accounts Payable (%)
Capital Expenditure -0.20-0-0.07-0.02-0.05-0.22-0.71-2.25-7.17-22.86
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.6,151
Beta 1.490
Diluted Shares Outstanding 12.83
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 10.998
Total Debt -
Total Equity 7.89
Total Capital 7.89
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 0.010.140.0200.010.040.140.451.434.57
EBITDA -14-7.28-8.84-8.720.08-30.13-96.02-305.99-975.07-3,107.18
EBIT -14.07-7.36-8.91-8.79--30.40-96.88-308.72-983.77-3,134.90
Tax Rate 11.52%0.00%0.00%0.00%0.00%2.30%2.30%2.30%2.30%2.30%
EBIAT -12.45-7.36-8.91-8.79--29.70-94.65-301.60-961.10-3,062.68
Depreciation 0.070.080.070.070.080.270.862.738.7027.72
Accounts Receivable ----------
Inventories ----------
Accounts Payable -0.040.26-0.08-0.442.055.1116.2951.90165.38
Capital Expenditure -0.20-0.01-0.07-0.02-0.05-0.22-0.71-2.25-7.17-22.86
UFCF -12.58-7.24-8.65-8.82-0.42-27.60-89.39-284.84-907.68-2,892.44
WACC
PV UFCF -0.42-24.86-72.55-208.27-597.92-1,716.52
SUM PV UFCF -2,620.12

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 11.00
Free cash flow (t + 1) -2,950.29
Terminal Value -32,780.98
Present Value of Terminal Value -19,453.92

Intrinsic Value

Enterprise Value -22,074.04
Net Debt -24.06
Equity Value -22,049.98
Shares Outstanding 12.83
Equity Value Per Share -1,718.52